We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

CERTEST BIOTEC

Certest Biotec, S.L. develops and manufactures IVD products in the human clinical testing field, including rapid test... read more Featured Products: More products

Download Mobile App





Certest Showcases Range of Rapid Tests and Real Time PCR Detection Kits at MEDICA 2021

By LabMedica International staff writers
Posted on 15 Nov 2021
Print article
Image: CerTest Rapid test (Photo courtesy of CerTest Biotec)
Image: CerTest Rapid test (Photo courtesy of CerTest Biotec)

CerTest Biotec (Zaragoza, Spain) showcased its range of rapid tests and real time PCR detection kits at the MEDICA 2021 trade fair held in Düsseldorf, Germany from 15-18th November. MEDICA is the world's largest medical trade fair for medical technology, electromedical equipment, laboratory equipment, diagnostics and pharmaceuticals.

CerTest highlighted different products for infectious diseases, tumor and inflammation markers detection. The company also presented its range of enzymes for molecular biology and qPCR. CerTest highlighted its range of monoclonal antibodies with high sensitivity and specificity by using highly stable and pure immunogens and an in-house improved screening; liquid recombinant proteins with high purity and stability, through a process of cloning, expression, multi-step purification and buffer optimization; native antigens -inactivated- comprising a wide variety of bacteria and viruses; and molecular biology enzymes with high specific activity and high stability, with and w/o glycerol that are suitable for qPCR and RT-qPCR.

CerTest also presents its rapid test diagnostic products for detecting the presence of antigens with the immunochromatographic lateral flow technique. These products included rapid diagnostic tests for gastrointestinal, respiratory infectious diseases, and the detection of inflammatory or tumor markers in the GI tract. The company demonstrated why its rapid tests are easy to use, along with its robust and stable diagnostic devices that are designed to provide the best performance in the simplest way and at the lowest associated operational costs. Also on display was CerTest’s Turbilatex product line including turbidimetric assays based on the agglutination reaction between antibody-coated latex particles and the antigen in solution, as well as reagents that permit a high-sensitivity detection method to be obtained. The intended use for Turbilatex products is to detect and quantify the antigen present in human stool samples.

Additionally, CerTest showcased its VIASURE Real Time PCR Detection Kits that are designed for the diagnosis of infectious diseases caused by different pathogens in human samples. This product range is based on 5’ nuclease chemistry. This technology utilizes two primers and a hydrolysis probe and exploits the exonuclease activity of Taq DNA polymerase. During the amplification, the increase in the fluorescent signal is proportional to the quantity of target sequence present in the sample and could be measured on a wide range of Real Time PCR platforms. VIASURE Real Time PCR Detection Kit contains in each well all the necessary components for Real Time PCR assay in a stabilized format, which allows the shipment at room temperature.

Related Links:
CerTest Biotec 

Gold Member
Troponin T QC
Troponin T Quality Control
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
LEISHMANIA Test
LEISHMANIA ELISA
New
3-Position Stirrer
ST-200 and SHP-200 Series

Print article

Channels

Molecular Diagnostics

view channel
Image: The test could be a game changer for people with some of the most aggressive forms of cancer (Photo courtesy of UNE)

Blood Test Could Help More Women Survive Aggressive Triple Negative Breast Cancer

Cancer research shows that over 90% of women diagnosed with breast cancer at its earliest stage survive for five years or more. However, this survival rate dramatically decreases to just 30% when the cancer... Read more

Pathology

view channel
Image: The Results Manager System (Photo courtesy of QuidelOrtho)

Informatics Solution Elevates Laboratory Efficiency and Patient Care

QuidelOrtho Corporation (San Diego, CA, USA) has introduced the QuidelOrtho Results Manager System, a cutting-edge informatics solution designed to meet the increasing demands of modern laboratories.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.